Sputnik V Covid vaccine 91.6% effective in Phase-III trial: Peer-reviewed data
(Photo: Reuters)
. Updated: 02 Feb 2021, 06:18 PM IST Agencies
Russia s Gamaleya Institute publishes peer-reviewed results of Sputnik V Covid-19 vaccine in the Lancet medical journal
The vaccine was found equally effective in people aged above 60, shows trial data
Share Via
Read Full Story
Russia s Sputnik V vaccine is 91.6 percent effective against symptomatic Covid-19 in Phase-III trial, according to peer-reviewed results published in The Lancet medical journal on Tuesday.
The preliminary findings show that the two-dose Sputnik V has shown high efficacy and was well tolerated for participants over 18 in final-stage clinical trials, said co-lead author Inna Dolzhikova of Russia s Gamaleya National Research Centre for Epidemiology and Microbiology.
Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial 2-Feb-2021 2:15 PM EST, by Lancet
Interim analysis from phase 3 trial of nearly 20,000 participants suggests efficacy of two-dose regimen of the adenovirus-based vaccine is 91.6% against symptomatic COVID-19 - trial reports 16 COVID-19 cases in the vaccine group (0.1% [16/14,964) and 62 cases (1.3% [62/4,902]) in the placebo group.
No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy.
Sub-analysis of 2,000 adults older than 60 years suggests the vaccine is similarly effective and well tolerated in this group.
Russia s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday. The findings are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo. Serious adverse events or those requiring hospital admission were rare in both the placebo and vaccine groups and none were considered associated with vaccination, the researchers said. Four deaths were reported in the trial, none of which were considered related to the vaccine, they said, adding most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy.
Russia’s Sputnik V vaccine is 91.6% effective against symptomatic Covid-19, interim trial results suggest
After criticism last year for an early rollout, Russia’s Sputnik V vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease, according to an interim analysis of the vaccine’s Phase 3 trial results.
The preliminary findings were published in The Lancet on Tuesday and are based on data gathered from 19,866 participants, of which around three-quarters (14,964) received two doses of the vaccine and a quarter (4,902) were given a placebo.
Sixteen cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after participants received the first vaccine dose. Sixty two cases were found in the placebo group equating to an efficacy of 91.6%.
The News Scroll 02 February 2021
Last Updated at 7:31 pm | Source: PTI
Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF Outlook February 02, 2021 19:31 IST Russian COVID vax found 91.6pc efficient in Phase III trial: RDIF outlookindia.com 1970-01-01T05:30:00+0530
New Delhi, Feb 2 (PTI) The Gamaleya National Research Centre and the Russian Direct Investment Fund (RDIF) on Tuesday said that interim results of a Phase III clinical trial of COVID-19 vaccine Sputnik V showed 91.6 per cent efficacy against the pandemic. Medical journal The Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine s high efficacy and safety, they said in a joint statement.